ID

31989

Description

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA); ODM derived from: https://clinicaltrials.gov/show/NCT01362153

Link

https://clinicaltrials.gov/show/NCT01362153

Keywords

  1. 10/10/18 10/10/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 10, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT01362153

Eligibility Rheumatoid Arthritis NCT01362153

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
have a diagnosis of ra for at least 3 months prior to screening
Description

Rheumatoid Arthritis Disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0872146
have no history of latent or active tuberculosis (tb) and test negative for tb
Description

Latent Tuberculosis Absent | Tuberculosis Absent | Tuberculosis test negative

Data type

boolean

Alias
UMLS CUI [1,1]
C1609538
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0041296
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C2242735
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
have inflammatory diseases other than ra
Description

Inflammatory disorder | Exception Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C1290884
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
have been treated with disease-modifying anti-rheumatic drugs (dmards)/systemic immunosuppressives other than methotrexate (mtx), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
Description

Antirheumatic Drugs, Disease-Modifying | Immunosuppressive Agents Systemic | Exception Methotrexate | Exception Sulfasalazine | Exception Hydroxychloroquine

Data type

boolean

Alias
UMLS CUI [1]
C0242708
UMLS CUI [2,1]
C0021081
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025677
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0036078
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0020336
have received intramuscular (im), iv, or intra-articular corticosteroids within 4 weeks of study agent administration
Description

Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous | Intraarticular injection of corticosteroids

Data type

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C1556154
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C1522726
UMLS CUI [3]
C2064783
have a known hypersensitivity to human ig proteins
Description

Human immunoglobulin allergy

Data type

boolean

Alias
UMLS CUI [1]
C0571543
have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
Description

infliximab | golimumab | adalimumab | abatacept | Etanercept | anakinra

Data type

boolean

Alias
UMLS CUI [1]
C0666743
UMLS CUI [2]
C2353893
UMLS CUI [3]
C1122087
UMLS CUI [4]
C1619966
UMLS CUI [5]
C0717758
UMLS CUI [6]
C0245109
have received alefacept, efalizumab, natalizumab, rituximab, or any b-cell-depleting agent
Description

alefacept | efalizumab | natalizumab | rituximab | B-cell depletion therapy

Data type

boolean

Alias
UMLS CUI [1]
C0962603
UMLS CUI [2]
C1174995
UMLS CUI [3]
C1172734
UMLS CUI [4]
C0393022
UMLS CUI [5]
C1171324
have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
Description

Biological agents | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0005515
UMLS CUI [2]
C0013230
have a history of latent or active granulomatous infection, including tuberculosis (tb), histoplasmosis, or coccidioidomycosis, prior to screening
Description

Granulomatous infection Latent | Granulomatous infection | Tuberculosis | Histoplasmosis | Coccidioidomycosis

Data type

boolean

Alias
UMLS CUI [1,1]
C1610637
UMLS CUI [1,2]
C0205275
UMLS CUI [2]
C1610637
UMLS CUI [3]
C0041296
UMLS CUI [4]
C0019655
UMLS CUI [5]
C0009186
have had a bacille calmette-guerin (bcg) vaccination within 12 months of screening
Description

Bacillus Calmette-Guerin vaccination

Data type

boolean

Alias
UMLS CUI [1]
C4305105
have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
Description

Communicable Disease Serious | Hepatitis | Pneumonia | Pyelonephritis | Sepsis

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [2]
C0019158
UMLS CUI [3]
C0032285
UMLS CUI [4]
C0034186
UMLS CUI [5]
C0243026

Similar models

Eligibility Rheumatoid Arthritis NCT01362153

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis Disease length
Item
have a diagnosis of ra for at least 3 months prior to screening
boolean
C0003873 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Latent Tuberculosis Absent | Tuberculosis Absent | Tuberculosis test negative
Item
have no history of latent or active tuberculosis (tb) and test negative for tb
boolean
C1609538 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0041296 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C2242735 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Inflammatory disorder | Exception Rheumatoid Arthritis
Item
have inflammatory diseases other than ra
boolean
C1290884 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
Antirheumatic Drugs, Disease-Modifying | Immunosuppressive Agents Systemic | Exception Methotrexate | Exception Sulfasalazine | Exception Hydroxychloroquine
Item
have been treated with disease-modifying anti-rheumatic drugs (dmards)/systemic immunosuppressives other than methotrexate (mtx), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
boolean
C0242708 (UMLS CUI [1])
C0021081 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025677 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0036078 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0020336 (UMLS CUI [5,2])
Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous | Intraarticular injection of corticosteroids
Item
have received intramuscular (im), iv, or intra-articular corticosteroids within 4 weeks of study agent administration
boolean
C0001617 (UMLS CUI [1,1])
C1556154 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C2064783 (UMLS CUI [3])
Human immunoglobulin allergy
Item
have a known hypersensitivity to human ig proteins
boolean
C0571543 (UMLS CUI [1])
infliximab | golimumab | adalimumab | abatacept | Etanercept | anakinra
Item
have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
boolean
C0666743 (UMLS CUI [1])
C2353893 (UMLS CUI [2])
C1122087 (UMLS CUI [3])
C1619966 (UMLS CUI [4])
C0717758 (UMLS CUI [5])
C0245109 (UMLS CUI [6])
alefacept | efalizumab | natalizumab | rituximab | B-cell depletion therapy
Item
have received alefacept, efalizumab, natalizumab, rituximab, or any b-cell-depleting agent
boolean
C0962603 (UMLS CUI [1])
C1174995 (UMLS CUI [2])
C1172734 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
C1171324 (UMLS CUI [5])
Biological agents | Investigational New Drugs
Item
have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
boolean
C0005515 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Granulomatous infection Latent | Granulomatous infection | Tuberculosis | Histoplasmosis | Coccidioidomycosis
Item
have a history of latent or active granulomatous infection, including tuberculosis (tb), histoplasmosis, or coccidioidomycosis, prior to screening
boolean
C1610637 (UMLS CUI [1,1])
C0205275 (UMLS CUI [1,2])
C1610637 (UMLS CUI [2])
C0041296 (UMLS CUI [3])
C0019655 (UMLS CUI [4])
C0009186 (UMLS CUI [5])
Bacillus Calmette-Guerin vaccination
Item
have had a bacille calmette-guerin (bcg) vaccination within 12 months of screening
boolean
C4305105 (UMLS CUI [1])
Communicable Disease Serious | Hepatitis | Pneumonia | Pyelonephritis | Sepsis
Item
have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0019158 (UMLS CUI [2])
C0032285 (UMLS CUI [3])
C0034186 (UMLS CUI [4])
C0243026 (UMLS CUI [5])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial